tbuckley/cabot-search huggingface dataset:
P2.13-020 Lung-RADS Used in Lung Cancer Screening: Does Granulomatous Disease Interferes with the Results? Initial Findings at a Brazilian Cancer Center
Authors: M. Guimaraes, T. Chulam, F. Haddad, P. Barbosa, A. Bitencourt, C. Tyng, J. Nochang, J. Folador, J. Gross
Journal: Journal of Thoracic Oncology (2017)
Using gene expression profiling to identify a prognostic molecular spectrum in gliomas
Authors: Mitsuaki Shirahata, Kyoko Iwao-Koizumi, Shigeyuki Oba, Sakae Saito, Noriko Ueno, Masashi Oda, Nobuo Hashimoto, Shin Ishii, Jun Takahashi, Kikuya Kato
Journal: Cancer Research (2008)

4425   Purpose: Because histopathological classification of gliomas is often clinically inadequate due to the diversity of tumors that fall within the same class, molecular prognostic factors are necessary for risk assessment of high-grade gliomas. The goal of this study was to identify prognostic molecular features in diffusely infiltrating gliomas using gene expression profiling.  Experimental design: We selected 3,456 genes expressed in gliomas, including 3,012 genes found in a glioma expressed sequence tag collection. The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive PCR, a high-throughput RT-PCR technique. The samples were mainly recruited from a phase II clinical trial of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy. We applied unsupervised and supervised principal component analyses to elucidate the prognostic molecular features of the gliomas.  Results: The gene expression data matrix was significantly correlated with the histological grades, oligo-astro histology, and prognosis. Using 110 gliomas, we constructed an outcome prediction model based on the expression profile of 58 genes, resulting in a scheme that reliably classified the glioblastomas into two distinct prognostic subgroups. The 58 genes were selected for correlation with progression-free survival by means of univariate Cox test. Genes involved in angiogenesis or tumor invasion process were up-regulated in the poor prognosis group, and those implicated in neuron-related function were up-regulated in the good prognosis group. The model was then tested with another 42 tissues. Multivariate Cox analysis of the glioblastoma patients using other clinical prognostic factors, including age and the extent of surgical resection, indicated that the gene expression profile was a strong and independent prognostic parameter. The methylation status of the MGMT promoter was not obviously correlated with our molecular classification. In addition, the model was also effective for prediction of the early progression in grade III cases. Finally, the model demonstrated a stable performance in two publicly availably data sets.  Conclusions: The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and oligodendroglial tumors that were more reliable than the traditional histological classification scheme.
P1.17-004 Extrapleural Pneumonectomy for Patients with Stage IVa Thymoma: Pathological Evaluation of Disseminated Pleural Nodules
Authors: S. Nakamura, H. Tateyama, K. Kawaguchi, T. Fukui, S. Hakiri, N. Ozeki, T. Kato, K. Yokoi
Journal: Journal of Thoracic Oncology (2017)
P1.16-025 Safety of Simultaneous TEVAR and Combined Aortic Wall Resection at the Time of Lung Resection for T4 Lung Cancer Infiltrating the Aorta
Authors: M. Tsuchida, T. Koike, S. Sato, T. Goto, A. Kitahara, A. Nakamura
Journal: Journal of Thoracic Oncology (2017)
ACTR-90. ROLE OF PHOTODYNAMIC THERAPY (PDT) USING TALAPORFIN SODIUM AND SEMICONDUCTOR LASER ON PROGNOSIS OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Masayuki Nitta, Yoshihiro Muragaki, Takashi Maruyama, Soko Ikuta, Hiroshi Iseki, Takayuki Yasuda, Takakazu Kawamata
Journal: Neuro-Oncology (2017)

Photodynamic therapy (PDT) is an emerging therapy that utilizes biochemical reactions between photosensitizer, light and tissue oxygen. PDT using Talaporfin sodium and semiconductor laser has shown dramatic anti-tumor effects for various cancers including lung cancer and esophageal cancer in Japan. We have conducted a prospective phase II trial of PDT for malignant brain tumors between 2009 and 2012, and PDT was approved for primary malignant brain tumors in 2013 in Japan. Since the approval, our institute has performed a prospective observation study of PDT for patients with newly diagnosed glioblastoma. Here, we report the clinical results of this prospective study. Patients with newly diagnosed glioblastoma who were treated with surgical removal of the tumor and PDT between March, 2009 and December 2016 were enrolled in this study. We compared the clinical results with patients with newly diagnosed glioblastoma who were treated with surgical removal of the tumor without PDT in same periods. Clinical results of 30 patients in the PDT group (15 males and 15 females) and 162 patients in the control group (102 males and 60 females) were analyzed. Patients who underwent biopsy was excluded. Median age of PDT and control group was 57 and 61 year old, respectively. EOR of the enhanced lesion was not significantly different in the two groups. The median progression free survival (PFS) of the PDT and the control group was 19.6 months and 8.9 months, respectively, and PDT group showed statistically significant better PFS (P=0.023). The median overall survival (OS) was significantly loner (P=0.037) in the PDT group (27.4 month) than the in the control group (22.1 months). There was no significant symptomatic adverse effect in the PDT group. PDT appears to provide significant survival benefit in patients with newly diagnosed glioblastoma. A randomized clinical trial is warranted.
P2.16-001 Liposomal Bupivacaine (Exparel) Reduces Thoracic Surgery Post-Operative Pain and Reduces Length of Stay, a Retrospetive Study
Authors: J. Aisner, J. Langenfeld, R. Nemoyer, J. Crystal, S. Mellender, A. Chiricolo, R. Jongco, E. Anton
Journal: Journal of Thoracic Oncology (2017)
P2.15-015 Negativity for Thyroid Transcription Factor 1 Was Correlated with Less Neuroendocrine Differentiation in Small Cell Lung Cancers
Authors: Y. Iida, N. Takahashi, Y. Nakanishi, H. Nishimaki, Y. Nakagawa, T. Shimizu, K. Mizumura, S. Maruoka, Y. Gon, S. Masuda, S. Hashimoto
Journal: Journal of Thoracic Oncology (2017)
Políticas de vacinação contra as infecções por pneumococos na Europa
Authors: R G Pebody, T Leino, H Nohynek, W Hellenbrand, S Salmaso, P Ruutu
Journal: Eurosurveillance (2005)

A infeccao por Streptococcus pneumoniae (Pneumococcus) e uma causa importante de manifestacoes clinicas invasivas como meningitis, septicemia e pneumonia, especialmente em criancas e pessoas de idade. Durante muitos anos, uma vacina polisacarida 23-valente (PPV) foi disponivel e desde 2001 uma vacina conjugada heptavalente (PCV) foi autorizada na Europa. Com o objectivo de conhecer a politica de vacinacao pneumococica na Europa, um questionario foi distribuido aos 15 Estados membros da Uniao Europeia (UE), Suica, Noruega e aos dez paises candidatos, como parte de um projecto financiado pela UE sobre a doenca pneumococica (Pnc-EURO). Vinte e tres dos 27 paises, parte da actual UE (mais a Noruega e a Suica) completaram o questionario. 
A vacina PPV era comercializada em 22 dos 23 paises que responderam e estava nas recomendacoes oficiais em 21. Em 20 dos 21 paises para os quais se dispunha da informacao a vacinacao estava orientada em direccao dos grupos de maior risco de infeccao. O numero de grupos de risco monitorizados oscilava entre 1 e 12. Ao menos 17 paises recomendam que a PPV seja administrada a todos os maiores de 65 anos (e em tres paises aos maiores de 60 anos). 
Treze paises elaboraram recomendacoes nacionais para a vacinacao com PCV em 2003. Ningum pais nesse momento recomenda a vacinacao infantil massiva, mas preferiam os grupos e especificos de risco (entre um e onze), particularmente as criancas com asplenia (n=13) e infeccao por VIH (n=12). O uso da PCV foi restringido a criancas de menos de dois anos em sete paises e de menos de cinco anos em quatro paises.
As decisoes futuras sobre o uso das vacinas pneumococicas na Europa serao tomadas com base a varios factores incluindo : carga local da doenca ; impacto previsto de qualquer programa universal, especialmente a importância da sustituicao do serotipo e a imunidade de grupo ; a eficacia de calendarios vacinais de doses reduzidas, e o custo da vacina. Ate hoje, ao menos um pais, Luxemburgo, tem implementado uma politica de vacinacao infantile universal com PCV.
SURG-04. CRANIAL BONE DEFECTS IN PATIENTS TREATED WITH TTFIELDS: A CASE SERIES
Authors: Niklas Thon, Martin Misch, Marscha Schlenter, Oliver Heese
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is the most abundant primary brain tumor with a devastating prognosis. Treatment of newly diagnosed GBM is generally based on maximal safe resection and subsequent concomitant chemoradiation followed by adjuvant temozolomide (TMZ). Tumor-treating-fields (TTFields) are a new treatment modality added to the temozolomide maintenance with proven efficacy in a large clinical trial. The therapy is based on anti-mitotic effects of alternating electric fields applied locally through so called transducer arrays being directly attached to the scalp. Patients with cranial bone defects, e.g. missing bone, were excluded from the clinical trial with TTFields and clinical experience regarding safety and feasibility is missing. We here report on cases with cranial defect on TTFields therapy. CASES: We observed four patients with recurrent GBM and missing cranial bone (female=1, male=3) at four different centers in Germany. The median age when starting the therapy was 55 years (range 51 - 69 years). All patients received first-line treatment at best clinical practice and experienced progressive disease. Craniectomy was indicated due to different reasons like inflammation or wound healing deficit. Thereafter, treatment with TTFields started in these patients at first and later recurrence. There were no severe adverse events observed in this population. The median monthly compliance was 83 % and with a range of 78 – 84 % compliance, all patients exceeded 75 % as suggested by study data to enable most efficient therapy. This multicentric and retrospective case series describes patients who were treated with TTFields despite a cranial bone defect. All patients were compliant to the therapy and there were no severe or additional side effects observed. Our observation provides first evidence that this setting is feasible and safe. Additional studies are warranted to increase clinical evidence for the safe use of TTFields in patients with cranial bone defects.
CSIG-14. HEPARAN SULFATE MODULATES CELL SIGNALING BY RECEPTOR TYROSINE KINASES IN HUMAN AND MURINE GLIOBLASTOMA
Authors: Yuki Ohkawa, Anna Wade, Olle R Lindberg, Katharine Chen, Vy M Tran, Joanna J Phillips
Journal: Neuro-Oncology (2017)

Heparan sulfate (HS) / Heparan sulfate proteoglycans (HSPGs) are implicated in tumor malignancy based on their ability to promote cell signaling and tumor invasion. The mechanisms by which they do this in an individual tumor type, however, are often poorly defined. Using both patient-derived glioblastoma (GBM) tumorsphere lines and a murine model for GBM, we investigate how cell surface HSPGs modulate cell signaling in infiltrating astrocytoma. In human tumorsphere lines, chemical ablation of cell surface HS reduced the phosphorylation of several receptor-tyrosine kinases (RTKs) including platelet-derived growth factor receptor α (PDGFRα). The reduction in PDGFRA activation was associated with decreased binding of tagged PDGF-BB ligand to the cell surface suggesting HS can promote ligand retention and activity at the cell surface. To ablate all HS production we established HS-deficient murine tumor-prone cells by knockout of Ext1, a glycosyltransferase required for HS chain elongation. HS-deficient cells had decreased growth in vitro, decreased invasion in a 3D spheroid invasion assays, and reduced activation of RTKs as detected by Western blotting compared to control cells. Preliminary in vivo experiments suggest HS-deficient cells also exhibit reduced growth in vivo and the structural role for HS in RTK signaling in glioma can now be addressed.
Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice
Authors: Aradhana Awasthi, Janet Ayello, Carmella van de Ven, Asana Love, Mitchell S. Cairo
Journal: Blood (2016)
P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors
Authors: A. Tessari, D. Palmieri, M. Pawlikowski, K. Parbhoo, C. Foray, M. Fassan, K. La Perle, E. Rulli, A. Fabbri, M. Ganzinelli, V. Embrione, M. Broggini, J. Amann, D. Carbone, M. Garassino, C. Croce, V. Coppola
Journal: Journal of Thoracic Oncology (2017)
Augmentation de l’incidence du VIH en Allemagne : les facteurs influençant la dynamique des contaminations
Authors: U Marcus, L Voss, C Kollan, O Hamouda
Journal: Eurosurveillance (2006)

Apres un pic initial au milieu des annees 1980, l’incidence du VIH chez les hommes ayant des relations sexuelles avec d’autres hommes (HSH) a baisse dans la plupart des pays industrialises occidentaux, puis s’est stabilisee pendant les annees 1990. Depuis la fin des annees 1990, un nombre croissant d’infections par le VIH nouvellement diagnostiquees chez les HSH ont ete observees dans la majorite des pays ayant des communautes homosexuelles importantes et visibles. 
En se basant sur une revue des etudes nationales et internationales sur la surveillance du comportement des HSH et sur les donnees nationales de surveillance du VIH, nous proposons un modele pour l’epidemie de VIH chez les homosexuels masculins en Allemagne.
Ce modele comprend des elements tels que le nombre croissant de partenaires sexuels et l’augmentation de la frequence des relations anales non protegees, l’utilisation conditionnelle du preservatif selon le statut VIH (reel ou percu) des partenaires (« serosorting ») ; la distribution des roles sexuels (actif ou passif selon le statut VIH) (« seropositioning »), le choix des partenaires et la formation de reseaux sexuels par le biais de la recherche de partenaires sexuels sur internet ; ainsi que l’introduction des nouvelles therapies antiretrovirales (Highly Active Antiretroviral Therapies, HAART) et les strategies de changement de ces therapies. Tous ces elements ont ete decrits, ou sont soupconnes d’avoir un role, dans l’augmentation ou la diminution du risque de transmission du VIH chez les HSH. 
En conclusion, il semble que l’augmentation recente de l’incidence du VIH chez les HSH a ete activee par une dissemination du VIH au sein des reseaux sexuels a haut risque, avec une proportion croissante d’infections transmises pendant la periode tres contagieuse du debut de la contamination par le VIH, acquise le plus souvent avec des partenaires sexuels occasionnels.
OA03.03 Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals
Authors: B. Mccall, C.L. Wilshire, C.C. Fuller, C.R. Gilbert, J.T. Fathi, J.R. Handy, K.E. Costas, B.E. Louie, R.W. Aye, A.S. Farivar, E. Vallières, J.A. Gorden
Journal: Journal of Thoracic Oncology (2017)
SCDT-02. BLOOD-BRAIN-BARRIER SPHEROIDS AS AN IN VITRO SCREENING PLATFORM FOR BRAIN-PENETRATING AGENTS
Authors: Choi-Fong Cho, Justin Wolfe, Colin Fadzen, David Calligaris, Kalvis Hornburg, E Antonio Chiocca, Nathalie Agar, Bradley Pentelute, Sean Lawler
Journal: Neuro-Oncology (2017)

The inability of most systemically delivered therapeutics to cross the blood-brain-barrier (BBB) is considered a major barrier to effective brain cancer treatment. In malignant glioma the tumor neovasculature is known to be leaky, however invasive cells remain protected behind an intact BBB, and continue to thrive within the brain, ultimately leading to tumor regrowth and patient death. This leaves us with an urgent unmet need for the development of next-generation therapeutics with improved brain delivery. For the first time, we describe here the utility of 3D multicellular BBB spheroids made of human brain endothelial cells (ECs), pericytes and astrocytes as a screening tool for brain-penetrating agents. We show that the outer surface of the spheroids, composed primarily of ECs and pericytes, form a tight barrier which is permeabilized in the presence of VEGF. The barrier is characterized by the presence of intact tight junctions and efflux-pump activity (i.e., P-glycoprotein). Furthermore, we have used this model to successfully demonstrate the transport of angiopep-2 (a well-known brain delivery vector) and its conjugates (containing cargoes of various sizes such as peptide, protein and affibody), thereby displaying the versatility of this model to screen and study a wide range of therapeutic agents. We demonstrate that this model is superior to the conventional transwell model in maintaining essential BBB characteristics (i.e., tight/adherens junctions and P-glycoprotein expression) and as a drug-screening tool. We have utilized the spheroid model to screen a panel of cell-penetrating peptides (CPPs) to identify several candidates with high brain-penetration potential. We then verified the ability of the top 4 candidate CPPs to cross the BBB in mice. This high-throughput model can lead to better design and analysis of first-in-class glioma therapeutics, and improve prediction of drug penetration in a living model, paving the way for breakthrough discoveries in brain cancer.
CSIG-34. PDGFRb SIGNALING MAINTAINS GLIOBLASTOMA SURVIVAL VIA HYPOXIA-INDUCED MITOPHAGY
Authors: Jinkyu Jung, Mark R Gilbert, Deric M Park
Journal: Neuro-Oncology (2017)

Platelet-derived growth factor (PDGF) signaling plays a key role in gliomagenesis. Glioblastomas express all PDGF ligands, and both cell membrane receptors, PDGFRα and PDGFRβ, that are involved in pro-survival autocrine and paracrine loops. Our previous work demonstrated that expression of PDGFRb is enriched in hypoxic glioblastoma tumor tissues. Also, induction of mitophagy is a well-known critical coping response to tissue hypoxia. We therefore investigated the role of PDGFRb signaling cascade in regulating hypoxia-induced mitophagy of glioblastoma. PDGFRb signaling was essential for induction of hypoxia-mediated mitophagy in glioblastoma cells. Western blotting and immunofluorescence imaging with either RNA interference of PDGFRb or treatment with PDGFRb inhibitor showed that NIX, a hypoxic responsive protein and regulator of mitophagy, was necessary for PDGFRb-mediated glioblastoma survival under hypoxia. Detecting MitoSOX and MitoTracker Green along with treatment of PDGFRb inhibitor suggested that inhibition of PDGFRb signaling pathway led to accumulation of mitochondrial ROS, and subsequently killing glioblastoma cells by suppressing mitophagy. In tumor bearing mice model, PDGFRb inhibitor attenuated growth of tumor mass, however, ectopic NIX expression reversed such effect. Furthermore, interference of mitophagic response by blocking PDGFRβ signaling enhanced cell death even in temozolomide-resistant tumor cells. This work suggests a potential mechanism by which PDGFRb inhibition could kill glioblastoma cells through suppression of NIX-mediated mitophagy. Manipulation of NIX and PDGFRb pathway may provide novel therapeutic opportunities in chemoresistant tumor models.
CMET-31. THE ROLE OF SURGERY IN THE COMBINED TREATMENT OF BRAIN METASTASES (BM). TWELVE YEARS NEUROSURGICAL EXPERIENCE
Authors: Carmine Carapella, Rosalinda Albanese, Stefano Telera, Laura Raus, Veronica Villani, Alessandra Fabi, Andrea Pace
Journal: Neuro-Oncology (2017)

Brain metastases represent the most common type of brain tumors, usually associated with a dismal prognosis (less than 10 months of OS) and progressive decrease of quality of life. Available data suggest that SRS and surgical resection are both excellent treatment options; surgery is favored in patients with lesions larger than 3 cm in diameter, located in posterior cranial fossa, with relevant mass effect. Finally, surgery could rule out radionecrosis, due to previously irradiation. In the last 12 years 251 BM patients underwent surgery at Neurosurgical Unit of our Institute; patients submitted to surgical resection were subsequently treated with different adjuvant therapies. This experience was analyzed in order to detect any change in type of tumors, therapeutic strategies and post-op complications. The series include 131 females and 120 males, median age at diagnosis was 59 (range 27–86). Non small cell lung cancer was the primary tumor in 37 % of the cases, followed by breast cancer in 23 % and melanoma in 14%. Infratentorial lesions were more frequent than reported in literature: 24 % vs 14%. Tumor resection offered in almost all cases immediate and long lasting relief from symptoms caused by increased intracranial pressure, without any major complications. The incidence of radionecrosis was 8%. In this period we did not observe any significant reduction of craniotomies and the location of the operated lesions remained roughly the same. Only in breast tumors there was a relevant reduction of the incidence of craniotomies due to more effective systemic treatments (p= 0.04). In our experience, surgery has maintained a significant role in the multidisciplinary treatment of BM, even after introduction of SRS. Surgery is particularly effective in rapidly reducing intracranial hypertension, improving neurologic functions, confirming diagnosis, mainly in patients with favorable prognostic features according to RPA.
Central and peripheral slow-pressor mechanisms contributing to Angiotensin II-salt hypertension in rats
Authors: Jiao Lu, Hong-Wei Wang, Monir Ahmad, Marzieh Keshtkar-Jahromi, Mordecai P Blaustein, John M Hamlyn, Frans H H Leenen
Journal: Cardiovascular Research (2017)

Abstract Aims High salt intake markedly enhances hypertension induced by angiotensin II (Ang II). We explored central and peripheral slow-pressor mechanisms which may be activated by Ang II and salt. Methods and results In protocol I, Wistar rats were infused subcutaneously with low-dose Ang II (150 ng/kg/min) and fed regular (0.4%) or high salt (2%) diet for 14 days. In protocol II, Ang II-high salt was combined with intracerebroventricular infusion of mineralocorticoid receptor (MR) blockers (eplerenone, spironolactone), epithelial sodium channel (ENaC) blocker (benzamil), angiotensin II type 1 receptor (AT1R) blocker (losartan) or vehicles. Ang II alone raised mean arterial pressure (MAP) ∼10 mmHg, but Ang II-high salt increased MAP ∼50 mmHg. Ang II-high salt elevated plasma corticosterone, aldosterone and endogenous ouabain but not Ang II alone. Both Ang II alone and Ang II-high salt increased mRNA and protein expression of CYP11B2 (aldosterone synthase gene) in the adrenal cortex but not of CYP11B1 (11-β-hydroxylase gene). In the aorta, Ang II-high salt increased sodium-calcium exchanger-1 (NCX1) protein. The Ang II-high salt induced increase in MAP was largely prevented by central infusion of MR blockers, benzamil or losartan. Central blockades significantly lowered plasma aldosterone and endogenous ouabain and markedly decreased Ang II-high salt induced CYP11B2 mRNA expression in the adrenal cortex and NCX1 protein in the aorta. Conclusion These results suggest that in Ang II-high salt hypertension, MR-ENaC-AT1R signalling in the brain increases circulating aldosterone and endogenous ouabain, and arterial NCX1. These factors can amplify blood pressure responses to centrally-induced sympatho-excitation and thereby contribute to severe hypertension.